PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
20-Oct-2025 Peer-Reviewed Journal of Clinical Psychiatry Publishes Mentavi's Online ADHD Diagnostic Evaluation Validation Study ACCESS Newswire
20-Oct-2025 Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors ACCESS Newswire
20-Oct-2025 Updated BEXMAB Phase I/II Data Presented at ESMO 2025 Shows Further Improvement, Strengthening the Clinical Profile of Bexmarilimab in Treatment-Naïve HR-MDS Patients ACCESS Newswire
20-Oct-2025 Genflow Biosciences PLC Announces Recognition of Patentability of Claims ACCESS Newswire
20-Oct-2025 Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia Businesswire
19-Oct-2025 Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial Businesswire
19-Oct-2025 ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy Businesswire
19-Oct-2025 XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer Businesswire
19-Oct-2025 Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer Businesswire
19-Oct-2025 Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 ACCESS Newswire
18-Oct-2025 KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery Businesswire
18-Oct-2025 Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025 Businesswire
18-Oct-2025 Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Businesswire
18-Oct-2025 Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress Businesswire
18-Oct-2025 Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 Businesswire
18-Oct-2025 Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer Businesswire
18-Oct-2025 Biden's DEA Wall of Marijuana Dishonor: The DEA Pattern of Corruption Is Now Impossible to Deny, President Trump Fixing ACCESS Newswire
18-Oct-2025 Sensient Announces Conference Call Businesswire
17-Oct-2025 Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss Businesswire
17-Oct-2025 MLTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Businesswire